Recent Updates in the Treatment of Follicular Lymphoma and Mantle Cell Lymphoma

Experts on follicular lymphoma discuss first-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Experts on follicular lymphoma discuss second-line treatment options available for patients.

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.